Business
Voyageur Pharmaceuticals Ltd. Announces Second Health Canada Approval and Issuance of Product License for HDXBa; Radiographic Barium Contrast
(TheNewswire) Calgary, Alberta - TheNewswire - Februa...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces Second Health Canada Approval and Issuance of Product License for HDXBa; Radiographic Barium Contrast \n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta\n \n \n -\n \n \n TheNewswire -\n \n \n February 16,\n2021\n \n \n -\n \n \n Voyageur Pharmaceuticals Ltd.\n \n \n (\n \n \n TSX\n \n \n V\n \n \n :\n \n \n VM\n \n \n )\n \n \n (\n \n \n OTC\n \n \n :\n \n \n \n VYYRF)\n \n \n \n (the \"Company\"\nor \"Voyageur\")\n \n \n is pleased to announce\nthat it has received approval from Health Canada for its second\nproduct, HDX\n \n \n Ba\n \n \n .  \nHDX\n \n \n Ba\n \n \n is a barium\nradiographic contrast powder for suspension that is specifically\nformulated for Fluoroscopy barium X-Ray procedures and can also be\nused for CT Scans.   This approval authorizes the sale of\nHDX\n \n \n Ba\n \n \n for use in radiology\nprocedures in Canada.   HDX\n \n \n Ba\n \n \n is specifically designed for X-Ray procedures of the entire\nupper and lower GI tract, including the stomach and duodenum for use\nin both adults and pediatric patients.\n \n \n \n \n This represents the second Health Canada licence\napproval for Voyageur, which has three additional barium radiographic\ncontrast products currently under review by Health Canada, with\napprovals expected forthcoming.\n \n \n \n \n “This approval is another key milestone to allow our\ncompany to transition to manufacturing and production” reports Brent\nWillis, Voyageur’s CEO.\n \n \n \n \n Voyageur has a strategic plan to advance through the\nstart-up phase of formulating, final testing of product and then\nmanufacturing.  This is expected to lead to full production\nmanufacturing, sales and distribution of barium contrast products\nnationally in the near term.\n \n \n \n \n About Voyageur\n \n \n \n \n Voyageur Pharmaceuticals Ltd. is Canadian public\ncompany listed on the TSX Venture Exchange under the trading symbol\nVM. Voyageur is focused on the development of barite and iodine,\nActive Pharmaceutical Ingredient (API) minerals. The near-term focus\nis developing barium and iodine radio-contrast pharmaceutical\nproducts.\n \n \n \n \n Voyageur’s goal is to initially generate the positive\ncash flow from operations using third party GMP pharmaceutical\nmanufac...